News

Thermo Fisher Scientific CFO Stephen Williamson expects 3% to 4% organic growth this year

Sunday, March 29, 2026 at 01:02 PM

Thermo Fisher Scientific's CFO provided growth projections during a financial discussion, noting a 2% organic growth rate for the previous year and forecasting 3% to 4% growth for the current year.

Context

On March 29, 2026, Thermo Fisher Scientific CFO Stephen Williamson reaffirmed the company's financial outlook, stating, "We delivered a little bit over 2% organic growth last year. We're expecting 3% to 4% growth this year." This guidance, originally detailed during the Q4 2025 earnings call, signals a measured recovery in the life sciences sector. The company's 2026 revenue target is set between $46.3 billion and $47.2 billion, supported by a $300 million foreign exchange tailwind and the anticipated mid-year close of the Clario acquisition. The projection reflects a strategic pivot toward high-growth areas, including a collaboration with OpenAI to integrate AI into drug development and the expansion of bioprocess centers in India. While Thermo Fisher reported 4% total revenue growth in 2025, the 2026 organic guidance suggests a "step up" in momentum. Investors remain focused on the company’s ability to navigate current tariffs and achieve its adjusted EPS guidance of $24.22–$24.80, representing 6%–8% annual growth.

Related Companies

Thermo Fisher
Thermo Fisher
TMO